The Danish drugmaker sued Hims in February over compounded versions of the Wegovy weight-loss pill that Hims launched and ...

Hims & Hers shares jumped more than 50% in premarket trade on Monday after ending a dispute with Novo Nordisk by striking a partnership with the Danish drug giant.

Hims & Hers Health partners with Novo Nordisk to sell weight loss medications, ending patent lawsuit. Shares surge 40% as companies reach agreement on Wegovy and Ozempic distribution.

Check out some of the companies making the biggest moves midday: Hims & Hers Health — Shares of the telehealth company jumped ...

Novo Nordisk has signed an agreement with Hims & Hers Health that will allow the telehealth provider to offer FDA‑approved versions of Ozempic and Wegovy at self‑pay prices comparable to other digital ...

There have been several stocks gaining investors' interest recently, including Hims and Hers Health (HIMS), Sterling Infrastructure (STRL), and Marvell Technology (MRVL). But why?

After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is making headlines as shares are surging in the wake of an agreement with GLP-1 maker ...

Novo Nordisk and Hims & Hers have come to an agreement that will see the telehealth company sell Novo’s branded glucagon-like ...

On February 17, 2026, BLKBRD Asset Management, LP, disclosed it sold out its entire stake in Hims & Hers Health (HIMS +5.89%), an estimated $18.07 million trade based on quarterly ...

Novo Nordisk drops its lawsuit against Hims & Hers as the companies partner to offer FDA-approved Wegovy and Ozempic through the telehealth platform.

Telehealth company Hims & Hers on Monday announced a “strategic shift” in its business model, partnering with pharmaceutical company Novo Nordisk to sell its blockbuster GLP-1 medication and stop ...

Whether President Trump signaled that he may soon end the military strikes is weighing on the minds of investors, executives and others.